Literature DB >> 2120689

Acquired von Willebrand disease associated with free lambda light chain monoclonal gammopathy, normal bleeding time and response to prednisone.

A K Stewart1, M F Glynn.   

Abstract

We report a case of acquired von Willebrand's syndrome with severe gastrointestinal bleeding and associated free monoclonal lambda light chains. The patient had a rapid sustained clinical and laboratory response to the administration of prednisone. Of note in this patient was the occurrence of angiodysplasia which has previously been reported in association with acquired von Willebrand's syndrome. No inhibitors of VWF:Ag, VWF:RCoF, or factor VIII:C were detected by mixing studies and the bleeding time was normal. Very few high molecular weight von Willebrand multimers were present prior to prednisone; however, the pattern reverted to a normal distribution following treatment. In appropriate patients with acquired von Willebrand's syndrome and monoclonal para-proteins, a trial of prednisone may be indicated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2120689      PMCID: PMC2429624          DOI: 10.1136/pgmj.66.777.560

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  14 in total

1.  A hemorrhagic syndrome in Waldenström's macroglobulinemia secondary to immunoadsorption of factor VIII. Recovery after splenectomy.

Authors:  J I Brody; M E Haidar; R E Rossman
Journal:  N Engl J Med       Date:  1979-02-22       Impact factor: 91.245

2.  Acquired Von Willebrand's syndrome associated with hairy cell leukaemia.

Authors:  J H Roussi; L L Houbouyan; R Alterescu; B Franc; A F Goguel
Journal:  Br J Haematol       Date:  1980-11       Impact factor: 6.998

3.  Acquired von Willebrand's syndrome.

Authors:  L Holland; A Adamson; G I Ingram; D G Chalmers
Journal:  Br J Haematol       Date:  1980-05       Impact factor: 6.998

4.  Acquired von Willebrand disease associated with an inhibitor to factor VIII antigen and gastrointestinal telangiectasia.

Authors:  K M McGrath; C A Johnson; J J Stuart
Journal:  Am J Med       Date:  1979-10       Impact factor: 4.965

5.  Acquired von Willebrand's syndrome with IgM inhibitor against von Willebrand's factor.

Authors:  M Gouault-Heilmann; M D Dumont; L Intrator; C Chenal; J L Lejonc
Journal:  J Clin Pathol       Date:  1979-10       Impact factor: 3.411

6.  Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody.

Authors:  W A Fricke; K M Brinkhous; J B Garris; H R Roberts
Journal:  Blood       Date:  1985-09       Impact factor: 22.113

7.  Acquired von Willebrand's disease in the myeloproliferative syndrome.

Authors:  U Budde; G Schaefer; N Mueller; H Egli; J Dent; Z Ruggeri; T Zimmerman
Journal:  Blood       Date:  1984-11       Impact factor: 22.113

8.  Acquired von Willebrand's disease: demonstration of a circulating inhibitor to the factor VIII complex in four cases.

Authors:  B M Sampson; M Greaves; R G Malia; F E Preston
Journal:  Br J Haematol       Date:  1983-06       Impact factor: 6.998

9.  Acquired von Willebrand's disease in association with Wilm's tumor: regression following treatment.

Authors:  J P Scott; R R Montgomery; D G Tubergen; T Hays
Journal:  Blood       Date:  1981-10       Impact factor: 22.113

10.  IgA inhibitor to factor VIII/von Willebrand factor.

Authors:  H R Gralnick; M A Flaum; C M Kessler; H Zimbler; B S Coller
Journal:  Br J Haematol       Date:  1985-01       Impact factor: 6.998

View more
  1 in total

Review 1.  Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.

Authors:  Hiroshi Mohri
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.